CIK 0001434316 · Non-accelerated filer<br>Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 651311552
- Phone
- 858.875.1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-10 | TAHL CINDY See Remarks | Sale | −5,654 | $1.55 | $9K | 336,707 |
| 2025-01-10 | Valamehr Bahram President and CEO | Sale | −8,705 | $1.54 | $13K | 349,364 |
| 2024-12-20 | Redmile Group, LLC Director | Other disposition | −1,084,936 | $1.68 | $1.8M | 11,743,010 |
| 2024-12-20 | Redmile Group, LLC Director | Other acquisition | +1,084,936 | $1.68 | $1.8M | 12,827,946 |
| 2024-12-20 | Redmile Group, LLC Director | Sale | −341,633 | $1.68 | $574K | 12,486,313 |
| 2024-12-20 | Redmile Group, LLC Director | Purchase | +397,964 | $1.68 | $669K | 12,884,277 |
| 2024-12-20 | Redmile Group, LLC Director | Other disposition · Class A Convertible Preferred Stock | −116,261 | $8.40 | $977K | 2,638,825 |
| 2024-12-20 | Redmile Group, LLC Director | Other acquisition · Class A Convertible Preferred Stock | +116,261 | $8.40 | $977K | 2,755,086 |
| 2024-12-20 | Redmile Group, LLC Director | Other disposition · Cash-settled Swaps | −56,331 | $1.68 | $95K | 502,769 |
| 2024-12-12 | Redmile Group, LLC Director | Conversion | +30,110 | 12,827,946 | ||
| 2024-12-12 | Redmile Group, LLC Director | Conversion · Class A Convertible Preferred Stock | −6,022 | 2,755,086 | ||
| 2024-08-06 | Xu Yuan Director | Sale 10b5-1 | −633 | $4.23 | $3K | 8,669 |
| 2024-07-29 | Valamehr Bahram Chief R&D Officer | Grant or award | +200,000 | 358,069 | ||
| 2024-07-29 | Mozaffarian Neelufar Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2024-07-29 | TAHL CINDY General Counsel and Secretary | Grant or award | +200,000 | 342,361 | ||
| 2024-06-07 | Lee Michael Stewart Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | Redmile Group, LLC Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | RASTETTER WILLIAM H Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | Jooss Karin Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | COUGHLIN TIMOTHY Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 |
Page 4 of 8 · 144 trades